CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Carvykti ciltacabtagene autoleucel Relapsed or refractory multiple myeloma Active
Casgevy exagamglogene autotemcel Sickle cell disease (SCD) Active
Casgevy exagamglogene autotemcel Transfusion-dependent β-thalassemia Active
Cayston Aztreonam for inhalation solution Cystic fibrosis, chronic pulmonary pseudomonas aeruginosa infections List with clinical criteria and/or conditions Complete
Celsentri Maraviroc HIV infection Do not list Complete
Celsentri Maraviroc HIV Withdrawn
Celsentri Maraviroc HIV List with clinical criteria and/or conditions Complete
Cerdelga Eliglustat Gaucher disease Reimburse with clinical criteria and/or conditions Complete
Champix Varenicline tartrate Smoking-cessation List with clinical criteria and/or conditions Complete
Cibinqo abrocitinib Atopic dermatitis, moderate to severe Reimburse with clinical criteria and/or conditions Complete
Last Updated : October 30, 2024